TBTuba Bulduk

Tuba Bulduk

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tuba Bulduk has a total of 23 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Retroperitoneal hematoma complicated with colocutaneous fistula in a case of severe hemophilia B

    by Haydar Zengin, Melda Cömert, Tuba Bulduk, Rahman Şenocak

    Retroperitoneal hematoma rarely occurs in hemophilia B cases caused by factor IX deficiency. It typically arises as a result of trauma or surgical procedures, though spontaneous cases are rare. We present our patient who developed spontaneous retroperitoneal hematoma and was subsequently complicated by abscess, coloenteric fistula, osteomyelitis and arteria lumbalis bleeding. Surgical intervention was avoided for a long time due to difficulty of hemophilia B management for surgery. Therefore, the complication became severe and life-threatening. The patient was treated with successful and long-lasting surgical interventions, intravenous antibiotics and factor IX replacements. To the best of our knowledge, the case we present is the first hemophilia patient in the literature complicated by colocutaneous fistula.

  • Open Access

    Real-life data of azacitidine-venetoclax combination in acute myeloid leukemia patients: a single center experience

    by Tuba Bulduk, Melda Cömert, Ebru Kiliç, Selim Sayin, Murat Yildirim, Meltem Ayli

    Aims: To evaluate real-life data on the efficacy and safety of Venetoclax (Ven) therapy used in combination with hypomethylating agent (HMA) in patients with acute myeloid leukemia (AML). Methods: The records of newly diagnosed, relapsed or refractory (RR) AML patients over 18 years of age who were planned to be treated with Azacitidine (AZA) combined with Ven because they were not suitable for intensive chemotherapy and patients who received AZA combined with Ven maintenance therapy after achieving remission were retrospectively analyzed. The standard protocol for patients is subcutaneous or intravenous AZA 75 mg/m2 on days 1-7/ every 28 days + oral Ven treatment 100-400 mg/day for 28 days. The treatment response rates, survival times, and side effect profiles of 18 newly diagnosed patients, 12 RR patients, and 4 patients receiving AZA+Ven as maintenance treatment between January 2021 and March 2022 were evaluated. Results: It was found that 8 of the 34 patients (23.5%) who were examined in the present study died before the first response could be evaluated. When the response rates were evaluated, complete response (CR) or complete remission with incomplete blood count recovery (CRi) (CR+CRi) was found to be 61% in the group receiving AZA+Ven in the first line, and CR+CRi was 50% in the group receiving AZA+Ven because of RR AML. In the group receiving AZA+Ven in the first line, the average Overall Survival (OS) was 8.00 months (95% CI: 1.58-14.41), and 7.00 months in the RR group (95% CI: 1.78-12, 21). All patients in the group receiving AZA+Ven for maintenance purposes were alive and the median follow-up period was 12.50±6.02 months in this group (Mean±SD). The most common side effect was neutropenia, and the most common cause of death was disease progression. Conclusion: In AML patients ineligible for intensive treatment due to advanced age or comorbidities, real-life data of AZA+Ven therapy with effective CR+CRi rates and a manageable spectrum of side effects promise hope.

  • History of the Hematology Proficiency Exam and the Turkish Experience

    by Tuba Bulduk, Ahmet Muzaffer Demi̇r, Neslihan Andic, Nilgün Saynalp, Meltem Ayli

    Objective: The purpose of the present paper was to provide information about the Turkish Society of Hematology Proficiency Exam and to raise awareness about continuing medical education and proficiency certification. Method: The data of the theoretical proficiency exams organized by the Turkish Society of Hematology since 2010 and the participation of Turkish hematologists in the European Hematology Examinations organized since 2017 were evaluated in the study. The number of hematology assistants and specialists who applied for the exam and the success levels of the participants were investigated. Results: A total of 10 Hematology Proficiency Written Exams have been administered since 2010 and a total of 108 candidates applied for the exam. A total of 53.7% (58 candidates) of the test takers were female and 46.3% (50 candidates) were male. According to the results of the proficiency exam that has been applied since 2010, almost all of the candidates (99%) were successful in the exam. The proficiency oral/practical exam was held for the first time on 29.04.2023. Conclusion: Proficiency exams are essential to provide an ideal level and standardization in hematology education. When compared to the European Hematology Examination, participation in the proficiency exam is lower than expected in our country. Hematologists should be encouraged to participate in the Hematology Proficiency Exam organized by the Hematology Medical Specialization Qualification Commission (HEM-TUYEK). Hematologists must also be supported to have a certificate of competence, which is an indicator of professionalism and continuous medical education.

  • Open Access

    The effects of hematological parameters and anticoagulant/antiaggregant use on surgical outcomes in acute subdural hematoma

    by Tuba Bulduk, Havva Nur Karaaslan

    Objective: This study aims to investigate the effect of hematologic parameters including International Normalized Ratio (INR), platelet (Plt), hemoglobin (Hb), hematocrit (Htc), mean corpuscular volume (MCV), leukocyte, neutrophil, lymphocyte, C-Reactive Protein (CRP) on the outcomes of surgical treatment of acute subdural hematoma. Material and Methods: The file data of 31 cases who were operated on with the diagnosis of Acute Subdural Hematoma (ASDH) at the Private Ankara Güven Hospital Neurosurgery Clinic between 01.01.2019 and 31.12.2021 were examined retrospectively. The ages, genders, history of anticoagulant/antiaggregant use, INR, platelet, hemoglobin, hematocrit, leukocyte, and CRP values of patients were recorded, and their relationships with re-bleeding, number of surgeries performed, and mortality were evaluated statistically. Results: The study was conducted with a total of 31 cases (35.5% (n=11) female and 64.5% (n=20) male). The average age of the cases was 72 (45-93). A single surgery was performed in 23 cases (74.2%), 8 patients (25.8%) were operated on again because of re-bleeding, and 9 of the cases (29%) died following the surgery. Among the 9 patients who died, 5 (55.5%) underwent single surgery and 4 (44.5%) underwent more than one surgery. The number of cases not using pre-operative anticoagulants/antiaggregants was 10 (32.3%), 9 (29%) patients were using anticoagulants, 7 patients (22.6%) were using single antiaggregant, and 5 patients (16.1%) were using dual antiaggregants. It was detected as statistically significant that the preoperative INR, leukocyte, and neutrophil counts of the patients who underwent multiple surgeries were detected to be higher than those of ASDH patients who underwent single surgery. Conclusion: Although pre-operative INR, leukocyte, and neutrophil elevation are not associated with mortality, these parameters can be associated with the requirement for re-surgery because of re-bleeding. Key words: re-bleeding, subdural hematoma, mortality, leukocyte, neutrophil

  • Open Access

    Aplastic anemia from past to the present: A bibliometric analysis with research trends and global productivity during 1980 to 2022

    by Tuba Bulduk

    There is no bibliometric study in the literature on Aplastic Anemia (AA). In the present study, the purpose was to summarize the intellectual structure of the subject, uncover the global productivity in this respect, and identify the latest research trends by performing a bibliometric analysis of the articles published on AA. For this purpose, outputs for different research components of scientific outputs (i.e., countries, institutions, journals, and authors) were analyzed. A total of 3221 articles on Aplastic Anemia published between 1980 and 2022 were analyzed by using various statistical methods and bibliometric approaches. The Spearman Correlation Coefficient was used for correlation analysis and bibliometric network visualization maps were used to identify trending topics, citation analysis, and international collaborations. The top 3 contributing countries to the literature were the USA in this respect (800, 24.8%), China (514, 15.9%), and Japan (442, 13.7%). The top 3 most active institutions were the National Institutes of Health USA (n = 177), National Heart Lung Blood Institute (n = 153), and Udice French Research Universities (n = 136). The top 3 most productive journals were the British Journal of Haematology (n = 239), Blood (n = 181), and Bone Marrow Transplantation (n = 137). The most prolific author was Neal Stuart Young (n = 130). Specific keywords that were most frequently used in articles were severe aplastic anemia, immunosuppressive therapy, pediatrics/children, anti-thymocyte globulin, cyclosporine, hematopoietic stem cell transplantation, myelodysplastic syndromes, Paroxysmal Nocturnal Hemoglobinuria, hepatitis-associated aplastic anemia, allogeneic stem cell transplantation, haploidentical hematopoietic stem cell transplantation, pancytopenia, eltrombopag, fludarabine, Graft-Versus-Host Disease, survival, apoptosis, cytokines, and cyclophosphamide. It was determined that the trend topics in recent years were eltrombopag, COVID-19, Treg, Th17, thrombopoietin receptor agonists, haploidentical hematopoietic stem cell transplantation, haploidentical donor/transplantation, and posttransplantation cyclophosphamide. In the formation of the AA literature, it was determined that the research leadership belonged to the USA, China, Japan, European countries (United Kingdom, Italy, Germany, France, Switzerland), India, and South Korea, which have large economies.


  • Open Access

    Association of Hematologic Parameters with Post-operative Outcomes in Patients Undergoing Lumbar Disc Herniation Surgery

    by Tuba Bulduk, Yiğit Aksoğan

    Objective: In this study, we aimed to determine whether hematologic parameters have an effect on the post-operative outcomes in patients operated for lumbar disc herniation. Material and Methods: The study was conducted in the retrospective cohort design in the Department of Neurosurgery of Ankara Güven Hospital and included patients who were hospitalized and treated with the diagnosis of Lumbar Disc Herniation (LDH) between 01.01.2019 and 31.12.2020. Patients' pre-operative hematologic parameters, which were routinely studied preoperatively, and Visual Analogue Scale (VAS) scoring records, which were routinely used to monitor pain levels, were retrospectively reviewed, and the outpatient clinic notes of the patients within 6 months post-operatively were evaluated. Results: Among 117 patients hospitalized with LDH over a 1-year period, 87 patients were included in the study. 30 LDH patients, owning factors that may affect wound healing and platelet function (active infection/diabetes mellitus, antiaggregants/anticoagulants) were excluded. When Hb was examined from the pre-operative hematological parameters, anemia was detected in 6 (7%) of 87 patients; however, it had no significant effects on VAS scores and surgical outcomes (p>0.05). Pre-operative Neutrophil-to-Lymphocyte Ratio (NLR) was elevated in 17 (20%) of the 87 patients, and the VAS score of these patients was found to be 1.5-fold higher than normal patients (p=0.031). Post-operative complications (infection, hemorrhage and cerebrospinal fluid fistula) were detected in 5 (6%) of the 87 patients who underwent surgery, and it was found that the pre-operative NLR values were high in these 5 patients. It was also found that high NLR increased the risk of post-operative complications 1.4-fold in patients (p=0.002). No results could be obtained regarding the platelet values because this parameter was within the normal range preoperatively in all patients. Conclusion: In the present study, the effects of hematological parameters on lumbar disc surgery were investigated, and it was concluded that elevated NLR values increased wound site infection among post-operative complications and VAS scores.

  • Poster: AML-179: Seasonal Association of Acute Promyelocytic Leukemia: A 6-Year Single-Center Experience

    by Melda Cömert, Ebru Kılıç Güneş, Murat Yıldırım, Bilge Uğur, Selim Sayın, Tuba Bulduk, Alparslan Merdin, Elifcan Aladağ Karakulak, Meltem Aylı

  • Open Access

    Does erythropoietin therapy affect circulating endothelial cells in hemodialysis patients?

    by T. Bulduk, A. U. Yalcin, O. M. Akay, S. G. Ozkurt, H. U. Teke, G. Sahin, G. Temiz, G. Demirel

    Anemia is a common complication of chronic kidney disease (CKD). The most common cause of anemia in CKD is erythropoietin deficiency; and the most important cause of mortality in CKD patients is atherosclerotic vascular complications which are associated with endothelial damage. One of the methods evaluating vascular integrity is the cytometric measurement of circulating endothelial cells and endothelial progenitor cells in peripheral blood. The study aimed to investigate the effects of erythropoietin therapy on endothelial dysfunction by evaluating circulating endothelial cells and endothelial progenitor cells in peripheral blood using the technique of flow cytometry. Methods. A total of 55 hemodialysis patients were evaluated in three groups; those having erythropoietin therapy for at least last 3 months (n = 20) / not having erythropoietin for at least the last 3 months (n = 20) and the patients who started erythropoietin treatment during the study (n = 5). The control group consisted of 20 people. Blood values of the 3rd Group were investigated three times as baseline, 2nd week and 8th week CD34 +, CD105 + cells were evaluated as activated circulating endothelial cells; CD133 +, CD146 + cells were evaluated as activated endothelial progenitor cells. Results. There was no difference between the patients and healthy individuals in terms of circulating endothelial cells and endothelial progenitor cells. In the third group, no differences were observed in circulating endothelial cells / endothelial progenitor cell levels at baseline / 2nd and 8th weeks. There was no correlation between erythropoietin and circulating endothelial cells / endothelial progenitor cells. Conclusion. A correlation is not available between the therapeutic doses of erythropoietin used in hemodialysis patients and circulating endothelial cells / endothelial progenitor cell levels; supratherapeutic doses could change the results.